These findings are consistent with previous reports of tumor uptake and retention using 123I-MIP-1095 in men with mCRPC [19] and extend our understanding of the tumor and normal tissue kinetics due to the longer half-lives of the radioiodine isotopes 124I and 131I. This distribution pattern of the tracer fits the PSMA expression profile previously reported for prostate cancer metastases and normal tissues [20–22]. This evidence concerns the gene FOLH1 and prostate carcinoma.